Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessCelularity Downgraded to Perform From Outperform

Celularity Downgraded to Perform From Outperform

Add to Favorite
Added to Favorite


Oppenheimer analysts downgraded Celularity Inc. (NASDAQ:CELU) to perform from outperform due to delays in the development of its CYNK-001 treatment for acute myeloid leukemia (AML). While early data on the treatment was encouraging, the company has struggled to differentiate itself in a competitive market and overcome obstacles in its development. The analysts also noted that there is still a lack of understanding about the potential of NK cells in treating solid cancers, although this could change with the emergence of new data in 2023.
The downgrade of Celularity reflects a broader downgrade of the NK cell therapy space, as companies in the field have faced delays and challenges in the development and clinical testing of their treatments.

Subscribe to get Latest News Updates

Latest News

You may like more
more

CWEB Urges Web Shoppers to Complete Purchases by Christmas Eve as Walmart Closes on Christmas Day

Walmart (WMT), the nation's largest retailer, will remain closed...

KULR Technology Group’s Recent Achievements and Market Performance

Benchmark upgraded KULR (AMEX:KULR) to a "Buy" rating, reflecting...

Conagra Brands, Inc. (NYSE:CAG) Surpasses Earnings Estimates

Conagra Brands, Inc. (NYSE:CAG) reported an EPS of $0.70,...